Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Repligen (NASDAQ:RGEN) posted its earnings results on Tuesday. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10, FiscalAI reports. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The firm had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the business posted $0.39 EPS. The business’s revenue was up 14.8% compared to the same quarter last year. Repligen updated its FY 2026 guidance to 1.970-2.050 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen reported strong Q1 results with $194M revenue (15% reported, 11% organic), 160 bps adjusted operating margin expansion, and raised full‑year adjusted EPS guidance to $1.97–$2.05.
• Management launched a Transformation Office to accelerate cost, manufacturing and IT/AI improvements, targeting at least 1 point of annualized margin benefit by end‑2027 and advancing the path to 30% adjusted EBITDA by 2030 (with ~$5–6M of non‑recurring charges).
• China and Asia Pacific momentum picked up meaningfully—China revenues nearly doubled in Q1 and the company signed an OEM partnership to expand local manufacturing and competitiveness beginning in 2027.
• Franchise strength was broad‑based and higher‑margin—analytics grew 50%+ (now guided to 20%+ for 2026), chromatography rose >25% (now guided >20%), and proteins delivered mid‑teens growth with expectations of low double‑digit growth for the year.
• Filtration/ATF growth was moderated for 2026 due to specific customer timing and a gene‑therapy headwind; the divestiture of the loss‑making Polymem business removes about $7M of FY revenue even as it improves margin outlook.

Repligen Stock Performance

RGEN traded up $9.05 during trading on Tuesday, hitting $127.26. 1,075,719 shares of the company traded hands, compared to its average volume of 869,476. The firm has a market cap of $7.18 billion, a P/E ratio of 149.91, a price-to-earnings-growth ratio of 2.28 and a beta of 1.09. The stock’s fifty day moving average is $121.56 and its 200 day moving average is $144.68. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. Repligen has a one year low of $109.50 and a one year high of $175.77.

Hedge Funds Weigh In On Repligen

Several institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC bought a new position in Repligen during the third quarter valued at about $368,387,000. Opti Capital Management LP bought a new position in Repligen during the fourth quarter valued at about $2,399,209,000. Invesco Ltd. grew its position in Repligen by 43.9% during the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after buying an additional 383,399 shares during the period. Finally, RTW Investments LP bought a new position in Repligen during the fourth quarter valued at about $174,347,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several recent analyst reports. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings lowered shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, March 3rd. Rothschild & Co Redburn set a $160.00 target price on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Roth Mkm initiated coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 target price for the company. Finally, Wells Fargo & Company reduced their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.25.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.